Vertex Pharmaceuticals Inc. buy stratec
Start price
14.01.18
/
50%
€142.77
Target price
11.01.19
€170.18
Performance (%)
18.71%
End price
11.01.19
€169.48
Summary
This prediction ended on 11.01.19 with a price of €169.48. The prediction had a final performance of 18.71%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 3.248% | 3.248% | 36.652% | 45.807% |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% | 64.061% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% | 86.918% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% | 77.872% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% | 68.192% |
Comments by stratec for this prediction
In the thread Vertex Pharmaceuticals Inc. diskutieren
Vertex wins expanded approval for its cystic fibrosis combo
Looking forward: VRTX moves the needle here with this approval. Now, it would appear as though the European approval matches that in America, and this can be a good tool for young patients with this form of cystic fibrosis. The $250,000+ price tag on Orkambi means that even with only reaching a third of the patients, the company stands to gain hundreds of millions in revenue a year from this.
stratec stimmt am 14.01.2018 der Outperform-Einschätzung der institutionellen Analysten aber mit dem Kursziel 188,67$ zu.
(Vom Mitglied beendet)
Stopped prediction by stratec for Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€414.00
09.04.25
09.04.25
€480.00
09.04.26
09.04.26
-5.02%
13.01.26
13.01.26
